利用二代测序对白塞病进行基因检测以识别单基因模拟病和HLA-B*51
该研究纳入英国四个白塞病专科中心的31例临床疑似白塞病患者,采用全外显子测序结合虚拟面板、Exomiser优先排序、拷贝数变异检测和HLA分型的工作流程。9/31(29%)患者检出模拟白塞病的单基因病,余22例中8例(36%)HLA-B*51阳性。作者认为基因检测可在白塞病诊断前识别单基因模拟病并影响治疗选择、预后和遗传咨询。
要点
- 31例临床疑似白塞病患者中9例(29%)检出单基因病,包括5例A20单倍剂量不足。
- 余22例患者中8例(36%)HLA-B*51阳性。
- 作者认为基因检测对白塞病诊断前的治疗选择、预后和遗传咨询有影响。
核心结论
- 作者描述了一种新的白塞病基因分析工作流程,可有效检测已知和潜在新的单基因型白塞病,同时提供HLA分型。
- 作者认为结果突显了白塞病诊断前进行基因检测的重要性,因其影响治疗选择、预后和遗传咨询。
研究设计与样本
- 从英国四个白塞病专科中心招募临床疑似白塞病患者,所有参与者接受全外显子测序。
- 遗传分析包括:用虚拟面板检查已知引起单基因免疫缺陷、自身炎症或血管炎的基因;用Exomiser结合人类表型本体(HPO)对变异进行优先排序;用ExomeDepth识别拷贝数变异;用OptiType进行HLA分型。
- 共招募31例患者,中位年龄15岁(范围4-52岁),中位发病年龄5岁(范围0-20岁)。
主要发现
- 9/31(29%)患者检出模拟白塞病的单基因病:5例A20单倍剂量不足伴新发TNFAIP3变异(p.T76I、p.M112Tfs*8、p.S548Dfs*128、p.C657Vfs*14、p.E661Nfs*36)。
- 1例ISG15缺陷伴新发无义变异(ISG15: p.Q16X)和1p36.33微缺失。
- 1例普通变异型免疫缺陷(TNFRSF13B: p.A181E)。
- 2例肿瘤坏死因子受体相关周期性综合征(TNFRSF1A: p.R92Q)。
- 余22例患者中8例(36%)HLA-B*51阳性。
临床怎么用
- 作者认为白塞病诊断前进行基因检测很重要,因其影响治疗选择、预后和遗传咨询。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Several monogenic autoinflammatory disorders and primary immunodeficiencies can present early in life with features that may be mistaken for Behçet's disease (BD). We aimed to develop a genetic analysis workflow to identify rare monogenic BD-like diseases and establish the contribution of HLA haplotype in a cohort of patients from the UK. METHODS: Patients with clinically suspected BD were recruited from four BD specialist care centres in the UK. All participants underwent whole-exome sequencing (WES), and genetic analysis thereafter by (i) examining genes known to cause monogenic immunodeficiency, autoinflammation or vasculitis by virtual panel application; (ii) scrutiny of variants prioritized by Exomiser using Human Phenotype Ontology (HPO); (iii) identification of copy number variants using ExomeDepth; and (iv) HLA-typing using OptiType. RESULTS: Thirty-one patients were recruited: median age 15 (4-52), and median disease onset age 5 (0-20). Nine/31 (29%) patients had monogenic disease mimicking BD: five cases of Haploinsufficiency of A20 with novel TNFAIP3 variants (p.T76I, p. M112Tfs*8, p. S548Dfs*128, p. C657Vfs*14, p. E661Nfs*36); one case of ISG15 deficiency with a novel nonsense variant (ISG15: p.Q16X) and 1p36.33 microdeletion; one case of common variable immune deficiency (TNFRSF13B: p.A181E); and two cases of TNF receptor-associated periodic syndrome (TNFRSF1A: p.R92Q). Of the remaining 22 patients, eight (36%) were HLA-B*51 positive. CONCLUSION: We describe a novel genetic workflow for BD, which can efficiently detect known and potentially novel monogenic forms of BD, whilst additionally providing HLA-typing. Our results highlight the importance of genetic testing before BD diagnosis, as this has an impact on choice of therapy, prognosis and genetic counselling.
引用
- Burleigh A, Omoyinmi E, Papadopoulou C, et al. Genetic testing of Behçet's disease using next-generation sequencing to identify monogenic mimics and HLA-B*51. Rheumatology (Oxford). 2024. PMID: 38006337. doi:10.1093/rheumatology/kead628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。